{"id":982170,"date":"2026-07-16T07:34:01","date_gmt":"2026-07-16T11:34:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/"},"modified":"2026-07-16T07:34:01","modified_gmt":"2026-07-16T11:34:01","slug":"briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/","title":{"rendered":"BriaCell Opens First Canadian Site \u2013 Sunnybrook \u2013 for Pivotal Phase 3 Trial in Metastatic Breast Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Sunnybrook\u2019s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell\u2019s pivotal Phase 3 clinical trial in metastatic breast cancer<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>BriaCell Phase 3 trial <\/em><br \/>\n          <\/strong><br \/>\n          <a href=\"https:\/\/feeds.issuerdirect.com\/news-release.html?newsid=8024473194415951&amp;symbol=BCTX\" rel=\"nofollow\" target=\"_blank\"><br \/>\n            <strong><br \/>\n              <em>featured in Nature Medicine<\/em><br \/>\n            <\/strong><br \/>\n          <\/a><br \/>\n          <strong><br \/>\n            <em> as one of \u201cEleven clinical trials that will shape medicine in 2026\u201d<\/em><br \/>\n          <\/strong>\n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, July  16, 2026  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre, a leading cancer center in Toronto, Ontario, Canada, has joined BriaCell\u2019s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=An8-A2QKPD7F5Cyu1fTB2ZNLMTsVs9mmnICZjxDLw3yM4PcYgNIAD9hbKWUcZU3JlByXgbu3Ntb_zGY8Rd6Qwry1wdY6Xa9Z4qNaf_woiX1i0Gx42NyphuDyE9QQCZcW\" rel=\"nofollow\" target=\"_blank\"><strong>NCT06072612<\/strong><\/a>).<\/p>\n<p align=\"justify\">In the United States, BriaCell\u2019s Phase 3 study now has over 80 active clinical sites across 15 states, including Penn Medicine&#8217;s Abramson Cancer Center, Mayo Clinic, Smilow Cancer Hospital at Yale New Haven, DHR Health Oncology Institute, Hematology Oncology Associates of Fredericksburg, Los Angeles Cancer Network, Manhattan Hematology\/Oncology Associates, New York Cancer &amp; Blood Specialists, Northwestern University, Sylvester Comprehensive Cancer Center (University of Miami), Texas Oncology-Baylor Charles A. Sammons Cancer Center, and the University of Arizona.<\/p>\n<p align=\"justify\">\u201cThere are a limited number of effective treatment options for patients with metastatic breast cancer and, unfortunately for most patients, standard treatments eventually stop working,\u201d commented Katarzyna Jerzak, MD, MSc, FRCPC, Medical Oncologist and Clinician Investigator at Sunnybrook\u2019s Odette Cancer Centre, and Associate Professor in the Department of Medicine, University of Toronto. \u201cWe are excited to evaluate BriaCell\u2019s innovative immunotherapy approach and to offer these patients the opportunity to access a potentially effective new treatment.\u201d<\/p>\n<p align=\"justify\">\u201cOpening our first Canadian clinical site for BriaCell\u2019s pivotal Phase 3 study is an important milestone,\u201d stated Dr. William V. Williams, BriaCell\u2019s President &amp; Chief Executive Officer. \u201cSunnybrook is a world-class cancer center, and its participation expands access to our Bria-IMT regimen to patients in Canada, as we work to accelerate development of this our novel immunotherapy for patients with metastatic breast cancer.\u201d<\/p>\n<p align=\"justify\">BriaCell\u2019s pivotal Phase 3 clinical study is evaluating BriaCell\u2019s lead clinical candidate, Bria-IMT\u2122, in combination with an immune checkpoint inhibitor (CPI), compared with physician\u2019s treatment of physician\u2019s choice in\u00a0patients with <strong>a<\/strong>dvanced metastatic\u00a0<strong>b<\/strong>reast\u00a0<strong>c<\/strong>ancer (the Bria-ABC study). The study\u2019s primary endpoint is overall survival (OS). An interim analysis is planned after 144 patient deaths have occurred, comparing mortality in patients treated with the Bria-IMT combination regimen versus those treated with physician\u2019s choice.<\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Svt5pjFDLOWzLn0AwbNHnWFi866thNQXMft_-mpAbSAizU_zFL_Wz4LScWZftUCvKkKiEmKrTBaJkjm312HtpwKMonF1Ue2g-cBeQtf7OplOzGwgP2KdUUyRRDlW_TtH4mdeEZT4vDnxQpJS6FQEvcc7EdL8J_mzPil9evZ_OB2LXSRE-YosoDmJbnu8f1On40VxRd2_1Vw-lrvrgbAAXO9Txyk_teYI1t0JNjkybOdYqmaQl1Y5Sazw5PFbHLEhNCd5SI_bVOtDpMdK-krVDCWsMq-lEnb_hJB0d6iik7Ot9kv_tYgffynJ2CFma6NnWAlWRkmNoJzTk8CLvHHa2oYEpwK8F0rZAV5-mmaTswmNbo-e9kUlNaJg3AfmlKfm\" rel=\"nofollow\" target=\"_blank\">BriaCell recently received a positive recommendation from the independent Data Safety Monitoring Board (DSMB) to continue the Phase 3 Study in metastatic breast cancer<\/a>.\u00a0At ASCO 2026, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Svt5pjFDLOWzLn0AwbNHnRRAydE9vHwX2uLyUlhP2VxqGzO324sAl5D8fKU8KuvfGC-tc9cQWAsTi62F69AC5pvHe3PrirNGpQDhrQmi-oFWmTGuOwr-F6jZQHu5P576-DNaLuSxNtlZaQ8cFMyQie_7QhQytHgxvxQgusfeWrr7j15Kn7BKEXJlHNG-BtpkIujScdxFZjQMfuJnm7BDovRhRMFW5t_ABRQfNeUFAKO1w0ZSDDasOOyIp3IFFfsJAlmdDAl8lrZZQ4F_yX4MAL54OptB9Dv8jZSeW7yBfuqorJD1pnqV-i6m7XjBczgv2-CEyHjR_Tnik3BCdjez3syyPRbRxjJezxq18TtL9SA=\" rel=\"nofollow\" target=\"_blank\">BriaCell reported positive Phase 2 survival data in a similar metastatic breast cancer patient population treated with the same Bria-IMT combination regimen<\/a>. The Bria-IMT combination regimen has received FDA Fast Track designation.<\/p>\n<p align=\"justify\">For additional information on BriaCell\u2019s pivotal Phase 3 study of Bria-IMT and an immune checkpoint inhibitor in metastatic breast cancer, please visit ClinicalTrials.gov\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=An8-A2QKPD7F5Cyu1fTB2Ww-Z1EMei32Ar77P_OBeWC0lIdM8tHabtN-s-Q9a_rOxdWSb5sgL8AUqNyaSZP3pfb4UiXOmcfiezehqbnPfWx0qsC-Mkw-nP21001N1PWz\" rel=\"nofollow\" target=\"_blank\"><strong>NCT06072612<\/strong><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6I9pXjFI2vl3VAtRzutIQ0CN3X2lLOglyaLl7OvTJ4F4OSQB3Ofr7iWxutK5I_eNXAnvODPw7uoUB356xgyJxVeBnsgUD5jcIJz5PznQ9Yc=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those regarding the participation of Sunnybrook\u2019s Odette Cancer Centre in BriaCell\u2019s ongoing pivotal Phase 3 study, the continued enrollment, advancement and outcomes of the Phase 3 study, the continued development and potential commercialization of Bria-IMT, and the potential benefits of Bria-IMT for patients with metastatic breast cancer, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company\u2019s profiles on SEDAR+ at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4sHRArVHlUoBDLXA0ExF8qRnMxuqRMdn6RyFI-59jHSMiHF7pU0ZkTnN4-lCiKUSfAKFzNuSwMXMNEhud2_4c6Ezv-4V4QSB7rqkkjx-a_8=\" rel=\"nofollow\" target=\"_blank\"><strong>www.sedarplus.ca<\/strong><\/a> and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4sHRArVHlUoBDLXA0ExF8vEaxw5xjhcXRHqCG83AMtZu9l6pFukwNHXTop3RXL19pL-M4QyxiA1sE7261rIpiQ==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=svzcHWzxh39kYnFaP-ZUd7Ih8-GCN_3qugsh_Z20XTqHAOPn8jRRM2hhZwNfghQv9R-WdbuNxNeyUZ7H4fJVhCIrddFgJEl1cldAFTunoBU=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_6XbYg0EQO9uYsaKybHf2E5nQm60u_0fV0PTGcaIC38-godsr2yZhEcG47_LzzaCZB7Kkoy6bB5Q8EZIXI6kKn7Xf8o8TVLZaU5tJ7q-Lxs=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzE5MSM3NzA4OTIwIzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWNmN2M0NTctODkwMS00OTI5LTg3YzAtNTA5NjZmZTYyYWU3LTExMDIyMjktMjAyNi0wNy0xNi1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sunnybrook\u2019s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell\u2019s pivotal Phase 3 clinical trial in metastatic breast cancer BriaCell Phase 3 trial featured in Nature Medicine as one of \u201cEleven clinical trials that will shape medicine in 2026\u201d PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre, a leading cancer center in Toronto, Ontario, Canada, has joined BriaCell\u2019s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier:\u00a0NCT06072612). In the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Opens First Canadian Site \u2013 Sunnybrook \u2013 for Pivotal Phase 3 Trial in Metastatic Breast Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-982170","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Opens First Canadian Site \u2013 Sunnybrook \u2013 for Pivotal Phase 3 Trial in Metastatic Breast Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Opens First Canadian Site \u2013 Sunnybrook \u2013 for Pivotal Phase 3 Trial in Metastatic Breast Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Sunnybrook\u2019s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell\u2019s pivotal Phase 3 clinical trial in metastatic breast cancer BriaCell Phase 3 trial featured in Nature Medicine as one of \u201cEleven clinical trials that will shape medicine in 2026\u201d PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre, a leading cancer center in Toronto, Ontario, Canada, has joined BriaCell\u2019s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier:\u00a0NCT06072612). In the &hellip; Continue reading &quot;BriaCell Opens First Canadian Site \u2013 Sunnybrook \u2013 for Pivotal Phase 3 Trial in Metastatic Breast Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T11:34:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzE5MSM3NzA4OTIwIzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Opens First Canadian Site \u2013 Sunnybrook \u2013 for Pivotal Phase 3 Trial in Metastatic Breast Cancer\",\"datePublished\":\"2026-07-16T11:34:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\\\/\"},\"wordCount\":880,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MzE5MSM3NzA4OTIwIzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\\\/\",\"name\":\"BriaCell Opens First Canadian Site \u2013 Sunnybrook \u2013 for Pivotal Phase 3 Trial in Metastatic Breast Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MzE5MSM3NzA4OTIwIzIwOTA2NTg=\",\"datePublished\":\"2026-07-16T11:34:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MzE5MSM3NzA4OTIwIzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MzE5MSM3NzA4OTIwIzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Opens First Canadian Site \u2013 Sunnybrook \u2013 for Pivotal Phase 3 Trial in Metastatic Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Opens First Canadian Site \u2013 Sunnybrook \u2013 for Pivotal Phase 3 Trial in Metastatic Breast Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Opens First Canadian Site \u2013 Sunnybrook \u2013 for Pivotal Phase 3 Trial in Metastatic Breast Cancer - Market Newsdesk","og_description":"Sunnybrook\u2019s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell\u2019s pivotal Phase 3 clinical trial in metastatic breast cancer BriaCell Phase 3 trial featured in Nature Medicine as one of \u201cEleven clinical trials that will shape medicine in 2026\u201d PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre, a leading cancer center in Toronto, Ontario, Canada, has joined BriaCell\u2019s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier:\u00a0NCT06072612). In the &hellip; Continue reading \"BriaCell Opens First Canadian Site \u2013 Sunnybrook \u2013 for Pivotal Phase 3 Trial in Metastatic Breast Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-16T11:34:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzE5MSM3NzA4OTIwIzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Opens First Canadian Site \u2013 Sunnybrook \u2013 for Pivotal Phase 3 Trial in Metastatic Breast Cancer","datePublished":"2026-07-16T11:34:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/"},"wordCount":880,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzE5MSM3NzA4OTIwIzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/","name":"BriaCell Opens First Canadian Site \u2013 Sunnybrook \u2013 for Pivotal Phase 3 Trial in Metastatic Breast Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzE5MSM3NzA4OTIwIzIwOTA2NTg=","datePublished":"2026-07-16T11:34:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzE5MSM3NzA4OTIwIzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzE5MSM3NzA4OTIwIzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Opens First Canadian Site \u2013 Sunnybrook \u2013 for Pivotal Phase 3 Trial in Metastatic Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/982170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=982170"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/982170\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=982170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=982170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=982170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}